FDA approval for leukaemia non-chemo combination therapy* Plus the latest pharma industry news & events

04 FEBRUARY 2019 | NEWSLETTER #6

THIS WEEK'S TOP STORIES

FDA approval for leukaemia non-chemo combination therapy The FDA has approved the first ever non-chemotherapy combination treatment using ibrutinib and obinutuzumab for the most common form of adult leukaemia…

UK biotech funding increased by 85 percent in 2018 UK-based biotech companies raised £2.2billion from investors in 2018, an increase of 85 percent from the year before, a report has found…

Implementing the Falsified Medicines Directive Implementation of the Falsified Medicines Directive is an important step in order to help prevent fraud in the pharmaceutical industry…

Benzodiazepines could decrease mortality in congestive heart failure   Researchers have suggested that benzodiazepines should be the first course of treatment for those with cardiovascular disease and anxiety…

Genetically modified viral injection could treat metastatic melanoma A study has reported that almost 40 percent of patients with non-surgically treatable tumours were effectively treated using a genetically modified virus…

Growing role of personalised and precision medicine in cancer treatments The role of personalised and precision medicine may be ideal for the treatment of cancer, but questions about consequences and society issues still remain…